# FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

> **NCT06636682** · PHASE2 · RECRUITING · sponsor: **Cellvax Therapeutics Inc** · enrollment: 100 (estimated)

## Conditions studied

- Prostate Cancer (Adenocarcinoma)
- Prostate CA
- Prostate Cancers
- Prostate Cancer (Post Prostatectomy)
- Prostate Cancer
- Prostate Cancer Patients Undergoing Radical Prostatectomy
- High-risk Prostate Cancer

## Interventions

- **BIOLOGICAL:** FK-PC101
- **BIOLOGICAL:** Standard of Care (SOC)

## Key facts

- **NCT ID:** NCT06636682
- **Lead sponsor:** Cellvax Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-14
- **Primary completion:** 2027-02-02
- **Final completion:** 2027-05-04
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06636682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06636682, "FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06636682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*